The funding will advance the company’s lead program targeted against NS4B, a specific region in the hepatitis C virus protein.
David Cory, president and CEO of Eiger, said: “We believe that disrupting the normal function of NS4B and NS5A proteins will lead to uniquely effective hepatitis C treatments. Our mission is to advance these novel small molecules into the clinic rapidly for the benefit of patients.”